One step closer to the new frontiers of healthcare for cardiomyopathy patients There were great advances in the treatment of heart failure (HF) over the past decades, characterised by the inclusion of ARNI and SGLT2 inhibitors in the latest guidelines. The use of cardiac myosin inhibitors specifically for patients with hypertrophic cardiomyopathy (HCM) is also making large steps forward, which reflects the next step towards more personalised treatment.
Roles for cardiologists in government, research councils and regulatory sectors Clinicians have numerous opportunities to gain experience in governmental or regulatory organisations, including health technology assessment bodies and payors. These organisations often seek advice from individuals with clinical experience and knowledge, and they increasingly engage with the clinical community on a regular basis. Cardiologists can also take on formal advisory roles, either through working groups or ad hoc and standing committees. Additionally, there may be part-time or full-time employment opportunities available, often providing leadership in research councils.
Al Stethoscope rolled out to 100 GP clinics to help diagnose heart failure GP clinics in London and Wales will receive an AI-powered tool as part of a trial to help improve the diagnosis of a deadly heart condition.
Classification Identifies Four Stages of Heart Attack The Canadian Cardiovascular Society (CCS) has developed a four-stage classification of acute atherothrombotic myocardial infarction (MI) based on the severity of the injury to the myocardium.
AHA Joins New Cardiovascular Certification Group ABCVM The American Heart Association (AHA) has now formally voted to join several other cardiovascular societies to form a new professional certification board for cardiovascular medicine, to be known as the American Board of Cardiovascular Medicine (ABCVM).
Coronary artery calcium: from risk prediction to treatment allocation and clinical trials Coronary artery calcium (CAC) is a direct measure of an individual’s coronary atherosclerotic burden.
FDA Okays First Extravascular ICD System The US Food and Drug Administration has approved Medtronic's novel "extravascular" implantable cardioverter-defibrillator (Aurora EV-ICD) system, which uses a single lead implanted substernally to allow anti-tachycardia pacing and low-energy defibrillation while avoiding the vascular space for lead placement.
New Tool to Guide Transcatheter Aortic Valve Replacement Researchers developed TJ-ICE–guided TAVR to facilitate implanting a heart valve at an optimal depth, guided by direct visualization of the membranous septum (MS) during the procedure.
Redefining CVD Risk: Cardiovascular-Kidney-Metabolic (CKM) Syndrome Citing the strong overlap between heart disease, kidney disease, type 2 diabetes, and obesity, the American Heart Association (AHA) has for the first time formally defined what they are calling cardiovascular-kidney-metabolic (CKM) syndrome.
ACP Revises Standard on Cardiorespiratory Death Determination The American College of Physicians (ACP) has issued a new position paper on determination of death that includes a clarification to the 1981 Uniform Determination of Death Act (UDDA), but otherwise reaffirms the current standards.